Jewim Pharmaceutical (Shandong) Co., Ltd

The main purpose of the study was to investigate the pharmacokinetics of beclomethasone formoterol inhalation aerosol (test preparation, 120 presses per bottle, each press contains 100μg beclomethasone dipropionate and 6μg formoterol fumarate) produced by Shandong Jingwei Pharmaceutical Co., Ltd. and beclomethasone formoterol inhalation aerosol (reference preparation, trade name: Qierchang®, 120 presses per bottle, each press contains 100μg beclomethasone dipropionate and 6μg formoterol fumarate) certified by Chiesi Farmaceutici SPA in healthy subjects after fasting administration, and to evaluate the bioequivalence of the two preparations. The secondary purpose of the study was to observe the safety of the test preparation beclomethasone formoterol inhalation aerosol and the reference preparation (Qierchang®) in healthy subjects.

To evaluate the pharmacokinetic characteristics and bioequivalence of the test formulation of eperisone hydrochloride tablets (specification: 50 mg, applicant: Shandong Jingwei Pharmaceutical Co., Ltd.) and the reference formulation (trade name: Myona®, specification: 50 mg, licensee: Eisai (China) Pharmaceutical Co., Ltd.) after a single oral dose under fed conditions in healthy Chinese adult subjects.

To evaluate the pharmacokinetic characteristics and bioequivalence of the test formulation (specification: 50 mg, applicant: Shandong Jingwei Pharmaceutical Co., Ltd.) and the reference formulation (trade name: Myona®, specification: 50 mg, licensee: Eisai (China) Pharmaceutical Co., Ltd.) after a single oral dose of eperisone hydrochloride tablets in healthy Chinese adult subjects under fasting conditions.